The Antiangiogenic Effect and Ocular Pharmacology of Novel Modified Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Oxygen-Induced Retinopathy
Journal of Ocular Pharmacology and Therapeutics · 2023
DOI: 10.1089/jop.2022.0113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, 2023. Verfasst von Wei Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Population and Preventive Medicine, Stony Brook University, Stony Brook, New York, USA. Hauptthemen laut MEDLINE: Retinal Diseases, Retinal Neovascularization, Retinopathy of Prematurity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To evaluate the hypothesis that 3 novel compounds, OXT-328, Q-922, and CL-717 show efficacy in the treatment of oxygen-induced retinopathy (OIR) and whether or not their route of administration is intravitreal, topical, or systemic.
Methods
The OIR mouse model, characterized by an avascular area (AVA) and a neovascular area (NVA) of the retina, was used to study retinopathy of prematurity and other retinal diseases characterized by abnormal vessel growth. We measured the effect of our compounds on both the AVA and NVA in whole mounts of mouse retinal tissue. We also evaluated their ability to prevent new vessel formation in chicken chorioallantoic membranes (CAMs). Finally, we measured the in vitro uptake and biodistribution of topically applied CL-717 in human eye explants.
Results
In mice with OIR, compared to controls, a single intravitreal administration of Q-922 or OXT-328 significantly reduced both AVA and NVA. CL-717 administered as eye drops over 5 days also reduced AVA and NVA, whereas OXT-328 eye drops had no effect. Q-922 given intraperitoneal (150 mg/kg/day × 5 days) reduced AVA and NVA. Remarkably, explanted human eyes bathed in CL-717 show rapid uptake and biodistribution in ocular tissues. In the chicken CAM model, all 3 compounds reduced the formation of new blood vessels by about one-third. No side effect in mice was observed, except for mild ocular surface irritation with Q-922.
Conclusions
Systemic administration of Q-922 or topical administration of CL-717 holds particular promise for a simplified treatment of proliferative retinopathies without the necessity of intravitreal injections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Population and Preventive Medicine, Stony Brook University, Stony Brook, New York, USA.
- Medicon Pharmaceuticals, Inc., Setauket, New York, USA.
- Department of Family, Population and Preventive Medicine, Stony Brook University, Stony Brook, New York, USA.
ORCID-Profile: Wei Huang, Basil Rigas
Zitieren
APA
Huang, W., Huang, L., Wen, Z., Honkanen, R. A., & Rigas, B. (2023). The Antiangiogenic Effect and Ocular Pharmacology of Novel Modified Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Oxygen-Induced Retinopathy. Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1089/jop.2022.0113
Vancouver
Huang W, Huang L, Wen Z, Honkanen RA, Rigas B. The Antiangiogenic Effect and Ocular Pharmacology of Novel Modified Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Oxygen-Induced Retinopathy. Journal of Ocular Pharmacology and Therapeutics. 2023. doi:10.1089/jop.2022.0113
BibTeX
@article{Huang2023,
author = {Huang, Wei and Huang, Liqun and Wen, Ziyi and Honkanen, Robert A and Rigas, Basil},
title = {The Antiangiogenic Effect and Ocular Pharmacology of Novel Modified Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Oxygen-Induced Retinopathy},
journal = {Journal of Ocular Pharmacology and Therapeutics},
year = {2023},
doi = {10.1089/jop.2022.0113}
}
EUVIMED